RNA interference-based therapeutics: new strategies to fight infectious disease.
For many years, there has been an ongoing search for new compounds that can selectively alter gene expression as a new way to treat human disease by addressing targets that are otherwise "undruggable" with traditional pharmaceutical approaches involving small molecules or proteins. RNA interference (RNAi) strategies have raised a lot of attention and several compounds are currently being tested in clinical trials. Viruses are the obvious target for RNAi-therapy, as most are difficult to treat with conventional drugs, they become rapidly resistant to drug treatment and their genes differ substantially from human genes, minimizing side effects. Antisense strategy offers very high target specificity, i.e., any viral sequence could potentially be targeted using the complementary oligonucleotide sequence. Consequently, new antisense-based therapeutics have the potential to lead a revolution in the anti-infective drug development field. Additionally, the relatively short turnaround for efficacy testing of potential RNAi molecules and that any pathogen is theoretically amenable to rapid targeting, make them invaluable tools for treating a wide range of diseases. This review will focus on some of the current efforts to treat infectious disease with RNAi-based therapies and some of the obstacles that have appeared on the road to successful clinical intervention.
López-Fraga
M
M
Sylentis S.A.U., Parque Tecnológico de Madrid, C/Santiago Grisolía n(o) 2, Tres Cantos 28760 (Madrid) - Spain. mlfraga33@gmail.com
Wright
N
N
Jiménez
A
A
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D020868:Gene Silencing / Q000187:drug effects; D005822:Genetic Vectors / Q000494:pharmacology; D006801:Humans; D007239:Infections / Q000188:drug therapy*; D010272:Parasitic Diseases / Q000188:drug therapy; D034622:RNA Interference / Q000187:drug effects*; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D014780:Viruses / Q000235:genetics
D000890:Anti-Infective Agents; D000998:Antiviral Agents; D034741:RNA, Small Interfering